30 May 2024
Kirkland Advises GTCR on Acquisition of Surmodics for Approximately $627 Million
Advising firms
Deal team
13 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Christopher Thomas Lead | Kirkland & Ellis | Partner | corporate | Not stated |
| Neil Vohra Lead | Kirkland & Ellis | Partner | corporate | Not stated |
| Sanford Perl | Kirkland & Ellis | Partner | corporate | Not stated |
| Michael Weed | Kirkland & Ellis | Partner | corporate | Not stated |
| Rachael Coffey | Kirkland & Ellis | Partner | corporate | Not stated |
| Katherine Kennedy | Kirkland & Ellis | Associate | corporate | Not stated |
| Jessica Lowe | Kirkland & Ellis | Associate | corporate | Not stated |
| Tom Dobleman | Kirkland & Ellis | Partner | debt finance | Not stated |
| Patrick Loughery | Kirkland & Ellis | Partner | debt finance | Not stated |
| Rachel Sheridan | Kirkland & Ellis | Partner | capital markets | Not stated |
| Polina Liberman | Kirkland & Ellis | Partner | tax | Not stated |
| Dennis Williams | Kirkland & Ellis | Partner | healthcare and life sciences regulatory | Not stated |
| Kate Hardey | Kirkland & Ellis | Partner | healthcare and life sciences regulatory | Not stated |
10 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 627m (approximately $627 million)
- What the figure measures
- Total transaction value
- Client
- GTCRBuy-side
- Counterparties
- Surmodics, Inc. (Sell-side)